Shenzhen Salubris Pharmaceuticals(002294.SZ): Innovative small molecule drug SAL0139 approved for clinical trials to treat hyperlipidemia

Shenzhen Salubris Pharmaceuticals(002294.SZ) announced that recently, the company has received the Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the company's independently developed innovative small molecule drug SAL0139 tablet (project code: SAL0139) to conduct clinical trials for the treatment of hyperlipidemia. Hyperlipidemia is a metabolic disease with hidden and widespread harm. If not controlled for a long time, it can lead to complications in multiple systems. The accumulation of low-density lipoprotein cholesterol (LDL-C) is a key risk factor for cardiovascular and cerebrovascular diseases. Preclinical studies have shown that SAL0139 has the potential to lower LDL-C. If successfully developed and approved for market launch, it is expected to provide new medication options for more patients, improve patient compliance, meet unmet clinical needs, and further enrich the company's innovative product pipeline in the field of chronic diseases.